Twenty point six percent of patients followed a switcher trajectory within 12 months, with higher persistence seen for switchers.

Diabetes and obesity drugs also lead to large reductions in adverse cardiovascular events, and the benefits aren’t just down ...

The use of glucagon-like peptide-1 (GLP-1) receptor agonists is associated with reduced risks for developing substance use disorders (SUDs).

The Chinese biotech put the idea to the test in a phase 2 trial of a subcutaneous depot formulation of its GLP-1 receptor agonist ASC30. U.S. investigators randomized 65 people with obesity or who ...

Results show increased long-term risk for osteoporosis, gout and osteomalacia in one study; improved postoperative outcomes for common orthopaedic procedures in another NEW ORLEANS, March 2, 2026 ...

For patients with cancer and brain metastases (BM) and type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 ...

Treatment with GLP-1 RAs for T2D and obesity is associated with increased risk for osteoporosis, gout, and osteomalacia compared with nonuse.

From 2023, there was a decrease in use of metabolic and bariatric surgery, with stronger decline for sleeve gastrectomy.

Here are five key takeaways for regarding the use of GLP-1 receptor agonists in patients who are undergoing breast cancer ...

Post-diagnosis weight gain over ~1.5 years is consistently associated with increased breast cancer–specific and all-cause mortality across meta-analyses. How GLP-1 weight-loss drugs fit after breast ...

Opportunities in the GLP-1 receptor agonist market include the development of new diabetes and obesity treatments with high ...

Among patients eligible for metabolic and bariatric surgery (MBS), glucagon-like peptide-1 receptor agonist (GLP-1 RA) ...